Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma.
Combined delivery of chemical drug and therapeutic gene has been introduced as an efficient method for the treatment of cancers such as glioblastoma. In this study, bis-chloroethylnitrosourea (BCNU) and vascular endothelial growth factor (VEGF) small interfering RNA (VEGF-siRNA) were co-delivered into C6 glioblastoma cells using a non-toxic peptide-based carrier. The R3V6 peptides, which are composed of 3-arginine and 6-valine, formed self-assembled micelles in aqueous solution. BCNU, a hydrophobic anti-cancer drug, was loaded into the hydrophobic core of the micelles, forming BCNU-loaded R3V6 micelles (R3V6-BCNU). In gel retardation assay, R3V6-BCNU formed a stable complex with siRNA. In vitro transfection assay showed that the VEGF-siRNA/R3V6-BCNU complex had the highest transfection efficiency into C6 cells at a 1:20 weight ratio (VEGF-siRNA:R3V6-BCNU). In addition, the VEGF-siRNA/R3V6-BCNU complexes had higher delivery efficiency than lipofectamine or naked siRNA. VEGF expressions were remarkably decreased by transfection of the VEGF-siRNA/R3V6 or VEGF-siRNA/R3V6-BCNU complexes. Furthermore, R3V6-BCNU delivered BCNU more efficiently into the cells than BCNU only. Therefore, R3V6 delivered both VEGF-siRNA and BCNU efficiently into the glioblastoma cells. The results suggest that R3V6-BCNU may be useful for combined delivery of siRNA and chemical drug into cancer cells.
Department of Bioengineering, College of Engineering, Hanyang University , Seoul , Republic of Korea.
Na
N
Yi
Binna
B
Oh
Hyun Ah
HA
Kim
Minhyung
M
Lee
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001120:Arginine / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods; D015316:Genetic Therapy / Q000379:methods; D005909:Glioblastoma / Q000188:drug therapy*; D057927:Hydrophobic and Hydrophilic Interactions; D008823:Micelles; D010455:Peptides / Q000008:administration & dosage*; D034741:RNA, Small Interfering / Q000008:administration & dosage*; D051381:Rats; D013501:Surface-Active Agents / Q000008:administration & dosage*; D014162:Transfection / Q000379:methods; D014633:Valine / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D008823:Micelles; D010455:Peptides; D034741:RNA, Small Interfering; D013501:Surface-Active Agents; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D001120:Arginine; D014633:Valine; D002330:Carmustine